REGEN-006
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with…
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
- Ages
- 30 Years - 80 Years
- Sexes
- All
aHUS REGISTRY
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
EMPA-KIDNEY
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the…
- Investigator
- Mark S Segal
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All